Construction of Highly Stable Cytotoxic Nuclear-Directed Ribonucleases

Ribonucleases are proteins whose use is promising in anticancer therapy. We have previously constructed different human pancreatic ribonuclease variants that are selectively cytotoxic for tumor cells by introducing a nuclear localization signal into their sequence. However, these modifications produ...

Descripción completa

Detalles Bibliográficos
Autores: Roura Padrosa, David, Castro Gallegos, Jessica, Romero Casañas, Alejandro, Ribó i Panosa, Marc, Vilanova i Brugués, Maria, Benito i Mundet, Antoni
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10256/16185
Acceso en línea:http://hdl.handle.net/10256/16185
Access Level:acceso abierto
Palabra clave:Ribonucleases
Citotoxicitat
Cytotoxicity
Càncer -- Tractament
Cancer -- Treatment
Cèl·lules canceroses
Cancer cells
Descripción
Sumario:Ribonucleases are proteins whose use is promising in anticancer therapy. We have previously constructed different human pancreatic ribonuclease variants that are selectively cytotoxic for tumor cells by introducing a nuclear localization signal into their sequence. However, these modifications produced an important decrease in their stability compromising their behavior in vivo. Here, we show that we can significantly increase the thermal stability of these cytotoxic proteins by introducing additional disulfide bonds by site-directed mutagenesis. One of these variants increases its thermal stability by around 17 °C, without affecting its catalytic activity while maintaining the cytotoxic activity against tumor cells. We also show that the most stable variant is significantly more resistant to proteolysis when incubated with proteinase K or with human sera, suggesting that its half-live could be increased in vivo once administered